Last edition
News about "lebrikizumab"
Eli Lilly and Company's Ebglyss Shows Four-Year Durable Relief in Atopic Dermatitis Study
Long-term phase III data reveal sustained skin clearance and itch reduction with once-monthly dosing in eczema patients.
Lebrikizumab | 30/03/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members